Feng Yang

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 29

Top Topics

Human Serum Albumin

Top Venues

Journal of medicinal chemistry

Molecular pharmaceutics

Molecules (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Ming Jiang, Wenjuan Li, Jinzhe Liang, Min Pang, Shanhe Li, Gang Xu, Minghui Zhu, Hong Liang, Zhenlei Zhang, Feng Yang
Developing a Palladium(II) Agent to Overcome Multidrug Resistance and Metastasis of Liver Tumor by Targeted Multiacting on Tumor Cell, Inactivating Cancer-Associated Fibroblast and Activating Immune Response. Journal of medicinal chemistry (2024)
Wenjuan Li, Ting Li, Ying Pan, Shanhe Li, Gang Xu, Zhenlei Zhang, Hong Liang, Feng Yang
Designing a Mitochondria-Targeted Theranostic Cyclometalated Iridium(III) Complex: Overcoming Cisplatin Resistance and Inhibiting Tumor Metastasis through Necroptosis and Immune Response. Journal of medicinal chemistry (2024)
Wenjuan Li, Shanhe Li, Minghui Zhu, Gang Xu, Xueyu Man, Zhenlei Zhang, Hong Liang, Feng Yang
Developing a Rhodium(III) Complex to Reprogram the Tumor Immune and Metabolic Microenvironments: Overcoming Multidrug Resistance and Metastasis in Non-Small Cell Lung Cancer. Journal of medicinal chemistry (2024)
Xueyu Man, Shanhe Li, Gang Xu, Wenjuan Li, Minghui Zhu, Zhenlei Zhang, Hong Liang, Feng Yang
Developing a Copper(II) Isopropyl 2-Pyridyl Ketone Thiosemicarbazone Compound Based on the IB Subdomain of Human Serum Albumin-Indomethacin Complex: Inhibiting Tumor Growth by Remodeling the Tumor Microenvironment. Journal of medicinal chemistry 67 (7) (2024)
Wenjuan Li, Ting Li, Ying Pan, Shanhe Li, Gang Xu, Zhenlei Zhang, Hong Liang, Feng Yang
Designing a Mitochondria-Targeted Theranostic Cyclometalated Iridium(III) Complex: Overcoming Cisplatin Resistance and Inhibiting Tumor Metastasis through Necroptosis and Immune Response. Journal of medicinal chemistry 67 (5) (2024)
Xueyu Man, Shanhe Li, Gang Xu, Wenjuan Li, Minghui Zhu, Zhenlei Zhang, Hong Liang, Feng Yang
Developing a Copper(II) Isopropyl 2-Pyridyl Ketone Thiosemicarbazone Compound Based on the IB Subdomain of Human Serum Albumin-Indomethacin Complex: Inhibiting Tumor Growth by Remodeling the Tumor Microenvironment. Journal of medicinal chemistry 67 (7) (2024)
Xueyu Man, Shanhe Li, Gang Xu, Wenjuan Li, Minghui Zhu, Zhenlei Zhang, Hong Liang, Feng Yang
Developing a Copper(II) Isopropyl 2-Pyridyl Ketone Thiosemicarbazone Compound Based on the IB Subdomain of Human Serum Albumin-Indomethacin Complex: Inhibiting Tumor Growth by Remodeling the Tumor Microenvironment. Journal of medicinal chemistry (2024)
Wenjuan Li, Ting Li, Ying Pan, Shanhe Li, Gang Xu, Zhenlei Zhang, Hong Liang, Feng Yang
Designing a Mitochondria-Targeted Theranostic Cyclometalated Iridium(III) Complex: Overcoming Cisplatin Resistance and Inhibiting Tumor Metastasis through Necroptosis and Immune Response. Journal of medicinal chemistry 67 (5) (2024)
Xueyu Man, Wenjuan Li, Minghui Zhu, Shanhe Li, Gang Xu, Zhenlei Zhang, Hong Liang, Feng Yang
Rational Design of a Hetero-multinuclear Gadolinium(III)-Copper(II) Complex: Integrating Magnetic Resonance Imaging, Photoacoustic Imaging, Mild Photothermal Therapy, Chemotherapy and Immunotherapy of Cancer. Journal of medicinal chemistry (2024)
Minghui Zhu, Xueyu Man, Yang Tongfu, Wenjuan Li, Shanhe Li, Gang Xu, Zhenlei Zhang, Hong Liang, Feng Yang
Developing a Hetero-Trinuclear Erbium(III)-Copper(II) Complex Based on Apoferritin: Targeted Photoacoustic Imaging and Multimodality Therapy of Tumor. Journal of medicinal chemistry (2023)
Wenjuan Li, Shanhe Li, Zhenlei Zhang, Gang Xu, Xueyu Man, Feng Yang, Hong Liang
Developing a Multitargeted Anticancer Palladium(II) Agent Based on the His-242 Residue in the IIA Subdomain of Human Serum Albumin. Journal of medicinal chemistry (2023)
Zhenlei Zhang, Juzheng Zhang, Tongfu Yang, Shanhe Li, Gang Xu, Hong Liang, Feng Yang
Developing an Anticancer Platinum(II) Compound Based on the Uniqueness of Human Serum Albumin. Journal of medicinal chemistry (2023)
Xueyu Man, Tongfu Yang, Wenjuan Li, Shanhe Li, Gang Xu, Zhenlei Zhang, Hong Liang, Feng Yang
Developing a Gadolinium(III) Compound Based on Apoferritin for Targeted Magnetic Resonance Imaging and Dual-Modal Therapy of Cancer. Journal of medicinal chemistry (2023)
Wenjuan Li, Shanhe Li, Gang Xu, Xueyu Man, Tongfu Yang, Zhenlei Zhang, Hong Liang, Feng Yang
Developing a Ruthenium(III) Complex to Trigger Gasdermin E-Mediated Pyroptosis and an Immune Response Based on Decitabine and Liposomes: Targeting Inhibition of Gastric Tumor Growth and Metastasis. Journal of medicinal chemistry (2023)
Zhenlei Zhang, Tongfu Yang, Juzheng Zhang, Wenjuan Li, Shanhe Li, Hongbin Sun, Hong Liang, Feng Yang
Developing a Novel Indium(III) Agent Based on Human Serum Albumin Nanoparticles: Integrating Bioimaging and Therapy. Journal of medicinal chemistry 65 (7) (2022)
Yi Gou, Xiaoying Jia, Li Xia Hou, Jun Gang Deng, Guo Jin Huang, Hao Wen Jiang, Feng Yang
Dithiocarbazate-Fe III , -Co III , -Ni II , and -Zn II Complexes: Design, Synthesis, Structure, and Anticancer Evaluation. Journal of medicinal chemistry 65 (9) (2022)
Tongfu Yang, Zhenlei Zhang, Juzheng Zhang, Yanping Li, Wenjuan Li, Hong Liang, Feng Yang
Developing a Gallium(III) Agent Based on the Properties of the Tumor Microenvironment and Lactoferrin: Achieving Two-Agent Co-delivery and Multi-targeted Combination Therapy of Cancer. Journal of medicinal chemistry (2022)
Tongfu Yang, Zhenlei Zhang, Juzheng Zhang, Yanping Li, Wenjuan Li, Hong Liang, Feng Yang
Developing a Gallium(III) Agent Based on the Properties of the Tumor Microenvironment and Lactoferrin: Achieving Two-Agent Co-delivery and Multi-targeted Combination Therapy of Cancer. Journal of medicinal chemistry 66 (1) (2022)
Tongfu Yang, Zhenlei Zhang, Juzheng Zhang, Yanping Li, Wenjuan Li, Hong Liang, Feng Yang
Developing a Gallium(III) Agent Based on the Properties of the Tumor Microenvironment and Lactoferrin: Achieving Two-Agent Co-delivery and Multi-targeted Combination Therapy of Cancer. Journal of medicinal chemistry 66 (1) (2022)
Ming Jiang, Zhenlei Zhang, Wenjuan Li, Xueyu Man, Hongbin Sun, Hong Liang, Feng Yang
Developing a Copper(II) Agent Based on His-146 and His-242 Residues of Human Serum Albumin Nanoparticles: Integration To Overcome Cisplatin Resistance and Inhibit the Metastasis of Nonsmall Cell Lung Cancer. Journal of medicinal chemistry 65 (13) (2022)
Tongfu Yang, Zhenlei Zhang, Juzheng Zhang, Yanping Li, Wenjuan Li, Hong Liang, Feng Yang
Developing a Gallium(III) Agent Based on the Properties of the Tumor Microenvironment and Lactoferrin: Achieving Two-Agent Co-delivery and Multi-targeted Combination Therapy of Cancer. Journal of medicinal chemistry 66 (1) (2022)
Juzheng Zhang, Ming Jiang, Shanhe Li, Zhenlei Zhang, Hongbin Sun, Feng Yang, Hong Liang
Developing a Novel Anticancer Gold(III) Agent to Integrate Chemotherapy and Immunotherapy. Journal of medicinal chemistry 64 (10) (2021)
Ming Jiang, Yong Chu, Tongfu Yang, Wenjuan Li, Zhenlei Zhang, Hongbin Sun, Hong Liang, Feng Yang
Developing a Novel Indium(III) Agent Based on Liposomes to Overcome Cisplatin-Induced Resistance in Breast Cancer by Multitargeting the Tumor Microenvironment Components. Journal of medicinal chemistry 64 (19) (2021)
Yi Gou, MeiRong Chen, Shanhe Li, JunGang Deng, Jinlong Li, GuiHua Fang, Feng Yang, GuoJin Huang
Dithiocarbazate-Copper Complexes for Bioimaging and Treatment of Pancreatic Cancer. Journal of medicinal chemistry 64 (9) (2021)
Muhammad Hamid Khan, Meiling Cai, Jungang Deng, Ping Yu, Hong Liang, Feng Yang
Correction: Khan et al. Anticancer Function and ROS-Mediated Multi-Targeting Anticancer Mechanisms of Copper (II) 2-hydroxy-1-naphthaldehyde Complexes. Molecules 2019, 24, 2544. Molecules (Basel, Switzerland) 26 (19) (2021)
Juzheng Zhang, Zhenlei Zhang, Ming Jiang, Shanhe Li, Haoliang Yuan, Hongbin Sun, Feng Yang, Hong Liang
Developing a Novel Gold(III) Agent to Treat Glioma Based on the Unique Properties of Apoferritin Nanoparticles: Inducing Lethal Autophagy and Apoptosis. Journal of medicinal chemistry 63 (22) (2020)
Zhenlei Zhang, Juzheng Zhang, Ming Jiang, Lei Zhao, Shanhe Li, Hongbin Sun, Feng Yang, Hong Liang
Human Serum Albumin-Based Dual-Agent Delivery Systems for Combination Therapy: Acting against Cancer Cells and Inhibiting Neovascularization in the Tumor Microenvironment. Molecular pharmaceutics 17 (4) (2020)
Zhenlei Zhang, Ping Yu, Yi Gou, Juzheng Zhang, Shanhe Li, Meiling Cai, Hongbin Sun, Feng Yang, Hong Liang
Novel Brain-Tumor-Inhibiting Copper(II) Compound Based on a Human Serum Albumin (HSA)-Cell Penetrating Peptide Conjugate. Journal of medicinal chemistry 62 (23) (2019)
Yi Gou, Yao Zhang, Zhenlei Zhang, Jun Wang, Zuping Zhou, Hong Liang, Feng Yang
Design of an Anticancer Copper(II) Prodrug Based on the Lys199 Residue of the Active Targeting Human Serum Albumin Nanoparticle Carrier. Molecular pharmaceutics 14 (6) (2017)